Introduction
============

Ovarian cancer accounts for about 4% of worldwide cancer incidence and mortality among women. As the seventh most common cancer and the eighth leading cause of cancer-related death in 2012 with 238,700 cases and 151,900 deaths,[@b1-cmar-10-5461] ovarian cancer has nonspecific symptoms, causing more than 60% of cases to be diagnosed at late stage, with a 5-year survival rate of 30%--40% in most countries.[@b2-cmar-10-5461] Ovarian clear cell carcinoma (OCCC) is considered a rather intriguing subtype among ovarian cancers due to its distinct histopathologic subtype, worse prognosis, and resistance to conventional platinum-based chemotherapy. Studies showed that OCCC has higher prevalence rate in East Asia (15%--25%) than in North America and Europe (1%--12%) due to race difference.[@b3-cmar-10-5461] OCCC occupies less than 5% of all ovarian cancers.[@b4-cmar-10-5461] An increased body mass index \>30 and endometriosis are associated with this histological subtype on the basis of several studies with an OR of 2.2--2.3.[@b5-cmar-10-5461]

High levels of vascular endothelial factor (vascular endothelial growth factor) expression were revealed in OCCC, correlating with shorter survival. Upregulation of IL-6/STAT-3/hypoxia-inducible factor signaling can also be found in OCCC, which is fundamental in hypoxia-induced angiogenesis.[@b6-cmar-10-5461] *HER2* is overexpressed in 14% of OCCCs,[@b7-cmar-10-5461] suggesting a further potential therapeutic agent. Regarding somatic mutations of OCCC, mutations of *PIK3CA* (32%--33%), *ARID1A* (46%), *KRAS*, and *BRAF* are frequently presented.[@b8-cmar-10-5461]--[@b10-cmar-10-5461]

Though rarely seen, reliable genetic diagnosis and target therapy for the precise treatment of OCCC patients are needed as its poor prognosis and resistance in chemotherapy. Both clinical approaches and genomic approaches are necessary in this quest.[@b11-cmar-10-5461] However, low incidence of OCCC and small number of samples bring obstacles in clinical trial, experimental research, and genomic analysis.

In this study, bioinformatical methods were applied to detect the differentially expressed genes (DEGs) between OCCC and normal human ovary tissue on gene expression profiling data downloaded from the Gene Expression Omnibus (GEO) database. Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and protein--protein interaction (PPI) network analysis were performed to detect novel indicators of OCCC patients and endeavor to provide potential therapeutic targets for this unique disease.

Materials and methods
=====================

Microarray data download and processing
---------------------------------------

The gene expression profiles of GSE6008, GSE29450, GSE18520, GSE54388, and GSE63885 were downloaded from GEO database (<https://www.ncbi.nlm.nih.gov/geo/>). GSE6008 was based on GPL96 \[HG-U133A\] Affymetrix Human Genome U133A array platform. GSE29450, GSE18520, GSE54388, and GSE63885 were based on GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 plus 2.0 array platform. GSE63885 contains no normal ovary tissue samples, while GSE18520 and GSE54388 contain no OCCC tissue samples; these three datasets were merged into one named "Dataset C" before further analysis. The original CDF files of the platform and CEL files of the arrays were downloaded from GEO website and Gene Chip Robust Multichip Average was used for normalization, which can adjust the background intensity and normalize the probe intensity of Affymetrix data in the merging process. The data after normalization are exported as Dataset C and analyzed. All datasets were renormalized at the probe level before analysis. All of the data were freely available online.

Tumor and normal ovary samples
------------------------------

Four tumor samples came from four OCCC patients treated at the Peking Union Medical College Hospital, Beijing, China. All patients had been treated with initial cytoreductive surgery followed by platinum-based chemotherapy. Four normal ovary tissue samples came from four benign disease patients surgically treated at the Peking Union Medical College Hospital. All samples were stored in liquid nitrogen tank after dissection. This study was approved by the ethics committee of Peking Union Medical College Hospital. All patients provided written informed consent before the study. This was conducted in accordance with the Declaration of Helsinki. All data were de-identified.

Data processing of DEGs
-----------------------

The GEO2R online analysis tool (<https://www.ncbi.nlm.nih.gov/geo/geo2r/>) was used to detect the DEGs between OCCC and normal samples, and the adjusted *P*-value and \|log2FC\| were calculated. Genes that met the cutoff criteria, adjusted *P*\<0.05 and \|log2FC\|\>2.0, were considered as DEGs. Each dataset owns unique DEGs. Venn diagram tool (online) (<http://bioinfogp.cnb.csic.es/tools/venny>) was used to analyze overlapping components.

GO and KEGG pathway analysis of DEGs
------------------------------------

GO analysis divides gene functions into biological process (BP), molecular function (MF), and cellular component (CC). KEGG analyzes genomes, biological pathways, diseases, chemical substances, and drugs on the DEGs. g:Profiler database (<https://biit.cs.ut.ee/gprofiler/>) and Cytoscape platform were used to identify the pathways and functional annotation of found genes and visualization of results. *P*\<0.05 and gene counts \>10 were considered statistically significant.

PPI network and module analysis
-------------------------------

To evaluate the interactive relationships among DEGs, we mapped the DEGs to the Search Tool for the Retrieval of Interacting Genes (STRING) database (<http://string-db.org/>) with a combined score \>0.4. PPI networks were constructed using the Cytoscape software. Nodes with higher degree of connectivity tend to be more essential in the functional network. The top six genes with degree of connectivity \>10 were identified as hub genes.

Real-time PCR
-------------

Total RNA was isolated from tissues with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Complementary DNA was synthesized by reverse transcription GoScript^™^ Reverse Transcription System (Promega, Madison, WS, USA). Quantitative real-time PCR (qPCR) analysis used the GoTaq^®^ qPCR Master Mix (Promega). The primer sets are shown in [Table S1](#SD1-cmar-10-5461){ref-type="supplementary-material"}. The PCR amplification was performed for 40 cycles of 95ºC for 5 seconds and 60ºC for 30 seconds, and melting curve reaction was performed at the end. All data analyses were operated using the 7500 Fast Real-Time PCR Systems (Applied Biosystems). The ΔΔ*Ct* method was used to assess the relative expression of different genes.

Western blotting analysis
-------------------------

Tissues were collected and lysed in RIPA (Thermo Fisher Scientific, Waltham, MA, USA) buffer supplemented with phenyl-methane-sulfonyl fluoride (Boster Biology, Pleasanton, CA, USA). The concentration of protein samples was detected using a BCA Protein Assay Kit (Beyotime Institute of Biotechnology). Equal amounts of lysates were separated by 10% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked for 1 hour in BSA blocking buffer (Solarbio Life Sciences, Beijing, China) and probed with primary antibodies (at a dilution of 1:1,000) at 4ºC for 12 hours (rabbit monoclonal to *WT1*, research resource identifier (RRID): ab89901; rabbit polyclonal to *SPP1*, RRID: ab8448; rabbit polyclonal to *DCN*, RRID: ab175404; rabbit polyclonal to *EPCAM*, RRID: ab71916; rabbit monoclonal to *ALDH1A1*, RRID: ab52492; rabbit polyclonal to Gata6, RRID: ab22600; and rabbit polyclonal to beta actin, RRID: ab8227). All were purchased from Abcam Corporation. Then they were incubated with the specific horse radish peroxidase (HRP)-conjugated secondary antibody (goat antirabbit IgG HRP \[ab6721\] from Abcam) for 2 hours before developing with the ECL kit (Merck Millipore, Kenilworth, NJ, USA). Data analysis was performed using ImageJ software to evaluate the expression levels of proteins. Statistical analysis was performed using SPSS 17.0 software (IBM Corp., Armonk, NY, USA) and with GraphPad Prism, version 5 (GraphPad Software). Statistically significant differences (*P*\<0.01) were determined by Student's *t*-test or ANOVA in the RT-PCR test and Western blotting analysis, presented as mean ± SD.

Results
=======

Identification of DEGs
----------------------

Five microarray datasets (GSE6008, GSE29450, GSE18520, GSE54388, and GSE63885) and the number of tumor and normal ovary tissue samples are shown in [Table 1](#t1-cmar-10-5461){ref-type="table"}. GSE63885 contains no normal ovary tissue samples. GSE18520 and GSE54388 contain no OCCC tissue samples. To accomplish the comparison between normal ovary tissue and tumor, these three datasets were merged into one named "Dataset C". The GEO2R online analysis tool was used to identify DEGs separately with the cutoff criteria, adjusted *P*\<0.05 and \|log2FC\|\>2.0 ([Table 1](#t1-cmar-10-5461){ref-type="table"}), to compare OCCC samples with normal ovary samples. DEGs expression heat maps and volcano plots are shown in [Figures 1](#f1-cmar-10-5461){ref-type="fig"} and [2](#f2-cmar-10-5461){ref-type="fig"}. Venn analysis was performed to get the intersection of the DEG profiles ([Figure 3](#f3-cmar-10-5461){ref-type="fig"}). Finally, 43 DEGs were significantly differentially expressed among all three groups, of which 30 were significantly upregulated genes and 13 were downregulated genes.

GO function and KEGG pathway enrichment analysis of DEGs g: Profiler were used to analyze GO function and KEGG pathway enrichment for DEGs ([Table 2](#t2-cmar-10-5461){ref-type="table"}). The enriched GO terms were divided into CC, BP, and MF ontologies. DEGs were mainly enriched in BPs, including tissue development, epithelium development, epithelial cell differentiation, tube development, organ development, and morphogenesis. MF analysis showed that the DEGs were significantly enriched in protein binding. For cell component, the DEGs were enriched in extracellular region, organelle, and space. The results of KEGG pathway analysis showed that DEGs were mainly enriched in extracellular matrix (ECM)-receptor interaction pathway and TGF-beta signaling pathway.

PPI network analysis
--------------------

To explore the potential relationship between the aberrantly expressed genes, we performed a PPI network analysis with the online software STRING (score \>0.4). Results were visualized by Cytoscape, as presented in [Figure 4](#f4-cmar-10-5461){ref-type="fig"}. The top six genes evaluated by connectivity degree in the PPI network were identified ([Table 3](#t3-cmar-10-5461){ref-type="table"}). Two of these hub genes (*SPP1*, *EPCAM*) are upregulated in OCCC.

RT-PCR and western blotting analysis
------------------------------------

We used four OCCC tumor tissue samples and four normal ovary tissue samples to evaluate the expression level of the six hub genes by RT-PCR and Western blotting analysis. As is shown in [Figure 5A, B](#f5-cmar-10-5461){ref-type="fig"}, mRNA and protein levels of both *SPP1* and *EPCAM* were significantly upregulated in carcinoma than normal tissues (*P*\<0.01). However, the other four downregulated genes showed no significant difference between two groups.

Discussion
==========

OCCC is a distinct histopathologic subtype of ovarian cancer. Other than the common characteristics of nonspecific symptoms and low survival rate of ovarian cancer, OCCC shows worse prognosis and resistance to conventional platinum-based chemotherapy, resulting in substantial obstacles for cancer treatment. Although OCCC only occupies less than 5% of all ovarian cancers, efforts have been devoted into the clinical and experimental research on OCCC, in which reliable genetic diagnosis and target therapy remain essential but unclear. Both clinical and genomic approaches are necessary in this quest. However, low incidence of OCCC and small number of samples bring obstacles in clinical trial, experimental research, and genomic analysis.

In the present study, five gene expression datasets were retrieved from GEO, including microarray information of 27 OCCC samples and 30 normal ovary samples. Gene expression and protein--protein expression analyses based on public databases were performed to identify potential key genes correlated with OCCC and screen out DEGs. We identified 30 upregulated DEGs and 13 downregulated DEGs, which were mainly enriched in BPs in GO analysis, including tissue development, epithelium development, epithelial cell differentiation, tube development, organ development, and morphogenesis. MF analysis showed that the DEGs were significantly enriched in protein binding. For cell component, the DEGs were enriched in extracellular region and organelle. The results of KEGG pathway analysis showed that DEGs were mainly enriched in ECM-receptor interaction pathway and TGF-beta signaling pathway.

By PPI network analysis, six hub genes were identified, including *WT1*, *SPP1*, *DCN*, *EPCAM*, *ALDH1A1*, and *GATA6*, two of which (*SPP1*, *EPCAM*) are upregulated in OCCC. Four OCCC tumor tissue samples and four normal ovary tissue samples were used to evaluate the expression level of the six hub genes by RT-PCR and Western blotting analysis. mRNA and protein levels of both *SPP1* and *EPCAM* were significantly upregulated in tumor than normal tissues while no significant expression difference between groups was found for the other four downregulated genes.

*EPCAM* is a epithelial cell adhesion molecule (CAM) that does not belong to any of the four CAMs families (cadherins, selectins, integrins, and immunoglobulin-like CAMs) and discovered as one of the first cancer markers.[@b12-cmar-10-5461] It is a cell surface glycoprotein of \~40 kDa and is highly expressed in epithelial cancers. *EPCAM* may play key roles in the progression of ovarian cancer through promoting migration, proliferation, inhibiting cell apoptosis and adhesion, and disturbing cell cycle. It may be used as specific therapeutic targets in the treatment of ovarian cancer.[@b13-cmar-10-5461] *EPCAM* is suggested to be the DEGs between ovarian carcinomas and normal ovarian epithelium, indicating its involvement in the pathogenesis of ovarian cancer.[@b14-cmar-10-5461],[@b15-cmar-10-5461] Battista et al found that overexpression of *EPCAM* retains its significance independent of established prognostic factors for longer progression-free survival (PFS) (HR, 0.408; 95% CI, 0.197--0.846; *P*=0.003) but not for PFS (HR, 0.666; 95% CI, 0.366--1.212; *P*=0.183).[@b16-cmar-10-5461] Another study indicated a significant association of *EPCAM* overexpression with a more favorable survival in epithelial ovarian cancer patients. Serous cancers showed a significant *EPCAM* overexpression compared with mucinous types in ovarian carcinoma.[@b17-cmar-10-5461] In addition, serum EPCAM level was found to be a diagnostic marker in epithelial ovarian cancer patients.[@b18-cmar-10-5461]

Secreted phosphoprotein 1 (*SPP1*) is a secreted arginine glycine aspartic acid containing phosphorylated glycoprotein, with a molecular weight of about 325 kDa.[@b19-cmar-10-5461] The human *SPP1* gene is located on chromosome 4 with seven exons and six introns.[@b20-cmar-10-5461] The expression of *SPP1* is strongly related to tumor metastasis in gastric cancer and esophageal adenocarcinoma.[@b21-cmar-10-5461]--[@b23-cmar-10-5461] Previous studies showed that *SPP1* is highly expressed in many kinds of tumors, such as colon cancer, prostate cancer, lung cancer, and breast cancer.[@b24-cmar-10-5461]--[@b26-cmar-10-5461] Modulation of vascular endothelial growth factor expression and regulation of extracellular matrix protein are the classic pathways in which *SPP1* facilitates cancer progression.[@b27-cmar-10-5461],[@b28-cmar-10-5461] Recent study of *SPP1* in epithelial ovarian cancer reveals that the expression of *SPP1* was higher in cancer tissues than in normal ovarian tissues. And it could be a useful biomarker in diagnosis of ovarian cancer with the diagnostic sensitivity and specificity of 0.66 (95% CI, 0.51--0.78) and 0.88 (95% CI, 0.78--0.93), respectively.[@b29-cmar-10-5461] Silencing *SPP1* decreased the cell proliferation, migration, and invasion in vitro and prevented ovarian cancer growth in mice, during which the integrin β1/FAK/AKT pathway was simultaneously inhibited.[@b30-cmar-10-5461] However, the expression and function of *SPP1* in OCCC remain unclear. Therefore, *SPP1* may be a prognostic factor and potential therapeutic target for OCCC. However, larger multicenter analysis is still needed to confirm these results.

In our study, *WT1*, *DCN*, *ALDH1A1*, and *GATA6* were downregulated in cancer compared to normal tissues by bioinformatic analysis. However, the RT-PCR and Western blotting analysis suggest otherwise. The role of these genes in OCCC is not clear. Experimental research of the biological functions of these genes in cancer cell lines is needed in the following study and can be illustrated in the future. Studies of large sample are required to evaluate the value of *SPP1*, *EPCAM*, and other genes in the prognostic evaluation and precise treatment of OCCC.

Conclusion
==========

Our research identified six hub genes as potential key genes of OCCC by bioinformatic analysis. *SPP1* and *EPCAM* are overexpressed in OCCC compared with normal ovary tissue. Experimental research is needed to reveal the biological functions of these genes in cancer cell lines. Clinical study of large sample is required to evaluate the value of *SPP1* and *EPCAM* in the precision treatment and prognostic influence on OCCC.

Supplementary material
======================

###### 

Primer set for RT-PCR

  Gene        Forward primer                 Reverse primer
  ----------- ------------------------------ -------------------------------
  *SPP1*      5′-CTCCATTGACTCGAACGACTC-3′    5′-CAGGTCTGCGAAACTTCTTAGAT-3′
  *WT1*       5′-CACAGCACAGGGTACGAGAG-3′     5′-CAAGAGTCGGGGCTACTCCA-3′
  *ALDH1A1*   5′-GCACGCCAGACTTACCTGTC-3′     5′-CCTCCTCAGTTGCAGGATTAAAG-3′
  *GATA6*     5′-CTCAGTTCCTACGCTTCGCAT-3′    5′-GTCGAGGTCAGTGAACAGCA-3′
  *DCN*       5′-ATGAAGGCCACTATCATCCTCC-3′   5′-GTCGCGGTCATCAGGAACTT-3′
  *EPCAM*     5′-AATCGTCAATGCCAGTGTACTT-3′   5′-TCTCATCGCAGTCAGGATCATAA-3′
  *GAPDH*     5′-GGAGCGAGATCCCTCCAAAAT-3′    5′-GGCTGTTGTCATACTTCTCATGG-3′

**Abbreviation:** RT-PCR, real-time PCR.
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![Heat maps of the differentially expressed genes of **(A)** GSE6008, **(B)** GSE29450, and **(C)** Dataset C.\
**Note:** Red: upregulation; green: downregulation.](cmar-10-5461Fig1){#f1-cmar-10-5461}

![Volcano plots of the differentially expressed genes of (**A**) GSE6008, (**B**) GSE29450, and (**C**) Dataset C.\
**Note:** Red: upregulation; green: downregulation.](cmar-10-5461Fig2){#f2-cmar-10-5461}

![Venn diagram of DEGs common to all three datasets.\
**Notes:** (**A**) Upregulated genes. (**B**) Downregulated genes.\
**Abbreviation:** DEGs, differentially expressed genes.](cmar-10-5461Fig3){#f3-cmar-10-5461}

![Protein--protein interaction network constructed with the differentially expressed genes.\
**Notes:** Red nodes represent upregulated genes. Green nodes represent downregulated genes.](cmar-10-5461Fig4){#f4-cmar-10-5461}

![The expression levels of proteins (**A**) and mRNAs (**B**) of six hub genes in two groups of samples.\
**Note:** \*Means the difference is statistically significant (*P*\<0.01).](cmar-10-5461Fig5){#f5-cmar-10-5461}

###### 

Three analyzed datasets and corresponding DEGs

  -------------------------------------------------------------------------------------------------
  Dataset ID   OCCC       Normal   Platform         Upregulated genes   Downregulated genes   
  ------------ ---------- -------- ---------------- ------------------- --------------------- -----
  GSE6008      8          4        HG-U133A         70                  53                    

  GSE29450     10         10       HG-U133_Plus_2   805                 599                   

  C            GSE18520   9        16               HG-U133_Plus_2      580                   231

  GSE54388\                                                                                   
  GSE63885                                                                                    
  -------------------------------------------------------------------------------------------------

**Abbreviations:** DEGs, differentially expressed genes; OCCC, ovarian clear cell carcinoma.

###### 

Significantly enriched GO terms and KEGG pathways of DEGs

  Classification   Term         Description                                           Counts   *P*-value
  ---------------- ------------ ----------------------------------------------------- -------- -----------
  BP term          GO:0009611   Response to wounding                                  9        3.56E-02
  BP term          GO:0071371   Cellular response to gonadotropin stimulus            3        2.68E-02
  BP term          GO:0009888   Tissue development                                    17       1.03E-03
  BP term          GO:0060429   Epithelium development                                12       3.60E-02
  BP term          GO:0030855   Epithelial cell differentiation                       10       1.32E-02
  BP term          GO:0003006   Developmental process involved in reproduction        10       3.93E-03
  BP term          GO:0007548   Sex differentiation                                   7        5.55E-03
  BP term          GO:0045137   Development of primary sexual characteristics         6        2.60E-02
  BP term          GO:0035295   Tube development                                      12       3.10E-03
  BP term          GO:0048513   Animal organ development                              19       3.33E-02
  BP term          GO:0009887   Animal organ morphogenesis                            12       3.59E-03
  BP term          GO:0048645   Animal organ formation                                5        2.98E-02
  BP term          GO:0061458   Reproductive system development                       9        1.09E-03
  BP term          GO:0048608   Reproductive structure development                    9        1.01E-03
  BP term          GO:0008406   Gonad development                                     6        2.22E-02
  BP term          GO:0001655   Urogenital system development                         8        1.19E-03
  BP term          GO:0072001   Renal system development                              8        4.64E-04
  BP term          GO:0001822   Kidney development                                    8        2.79E-04
  BP term          GO:0090183   Regulation of kidney development                      4        1.59E-02
  BP term          GO:0001823   Mesonephros development                               5        8.41E-03
  BP term          GO:0072006   Nephron development                                   5        3.44E-02
  BP term          GO:0032835   Glomerulus development                                4        2.61E-02
  BP term          GO:0072012   Glomerulus vasculature development                    3        4.87E-02
  BP term          GO:0072073   Kidney epithelium development                         6        1.61E-03
  BP term          GO:0072163   Mesonephric epithelium development                    5        6.90E-03
  BP term          GO:0072164   Mesonephric tubule development                        5        6.90E-03
  BP term          GO:0001657   Ureteric bud development                              5        6.56E-03
  BP term          GO:0061005   Cell differentiation involved in kidney development   4        1.71E-02
  BP term          GO:0046661   Male sex differentiation                              5        3.97E-03
  BP term          GO:0046546   Development of primary male sexual characteristics    5        1.68E-03
  BP term          GO:0008584   Male gonad development                                5        1.61E-03
  BP term          GO:0090184   Positive regulation of kidney development             4        4.56E-03
  CC term          GO:0005576   Extracellular region                                  25       1.50E-02
  CC term          GO:0044421   Extracellular region part                             25       4.27E-04
  CC term          GO:0043230   Extracellular organelle                               21       2.45E-04
  CC term          GO:0005615   Extracellular space                                   25       1.88E-04
  CC term          GO:1903561   Extracellular vesicle                                 21       2.41E-04
  CC term          GO:0070062   Extracellular exosome                                 21       2.14E-04
  CC term          GO:0005796   Golgi lumen                                           5        7.62E-03
  MF term          GO:0005515   Protein binding                                       39       8.79E-03
  KEGG_PATHWAY     hsa04512     ECM-receptor interaction                              3        0.0384428
  KEGG_PATHWAY     hsa04350     TGF-beta signaling pathway                            3        0.0409828

**Abbreviations:** BP, biological process; CC, cellular component; DEGs, differentially expressed genes; ECM, extracellular matrix; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.

###### 

Top six hub genes with higher degree of connectivity

  Gene symbol   Gene description                            Degree
  ------------- ------------------------------------------- --------
  WT1           Wilms tumor 1                               15
  SPP1          Secreted phosphoprotein 1                   14
  DCN           Decorin                                     12
  EPCAM         Epithelial cell adhesion molecule           12
  ALDH1A1       Aldehyde dehydrogenase 1 family member A1   10
  GATA6         GATA-binding protein 6                      10
